Vanguard Group Inc Aprea Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 10, 2023	BUY	$0.32 - $15.2 $137 - $6,551	431 Added 0.14%	310,029 $102,000
Q3 2022 Nov 14, 2022	SELL	$0.71 - $13.6 $32,583 - $624,131	-45,892 Reduced 12.91%	309,598 $201,000
Q1 2022 May 13, 2022	SELL	$1.59 - $3.16 $542,724 - $1.08 Million	-341,336 Reduced 48.98%	355,490 $662,000
Q4 2021 Feb 14, 2022	SELL	$2.87 - $5.58 $59,090 - $114,886	-20,589 Reduced 2.87%	696,826 $2 Million
Q3 2021 Nov 12, 2021	BUY	$3.43 - $5.63 $34,275 - $56,260	9,993 Added 1.41%	717,415 $3.67 Million
Q2 2021 Aug 13, 2021	BUY	$4.05 - $5.5 $2.87 Million - $3.89 Million	707,422 New	707,422 $3.45 Million

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$3,865
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.